India’s leading animal health company, Multiples PE-backed Zenex Animal Health India Private Limited, has acquired a majority stake in Netherlands-based VievePharm, a specialist in natural animal nutrition, in a move set to accelerate its global expansion. The financial terms of the deal were not disclosed.
Headquartered in Enter, VievePharm is renowned for its phytogenic formulations across livestock, equine, and pet care markets. Its GMP+, FSA, and Skal-certified facility serves more than 60 customers across 25 countries in Europe and beyond, offering Zenex a new manufacturing and sales hub in Western Europe.
The acquisition strengthens Zenex across three strategic pillars:
Expanding the “Naturals” Portfolio: VievePharm’s phytogenic expertise complements Zenex’s Ayurvedic offerings acquired via Ayurvet in 2023. With the EU’s Farm to Fork Strategy aiming to cut veterinary antibiotic sales by 50% by 2030, this portfolio is positioned for strong market tailwinds.
Advanced Bolus Manufacturing: VievePharm is a leader in high-quality bolus production. Their Dutch facility provides sophisticated delivery technology for minerals, vitamins, and udder health support, which Zenex plans to leverage globally.
Western European Footprint and Export Growth: VievePharm offers Zenex a strategic gateway into Western Europe, enabling faster distribution of its therapeutic and nutritional products—including powders, liquids, and boluses—across the EU.
Dr. Arun Atrey, Managing Director and CEO of Zenex Animal Health, said, “The acquisition of VievePharm is a logical progression of our first-principles approach to animal healthcare—focusing on prevention and sustainable productivity. By combining VievePharm’s advanced bolus technology and European market access with our R&D depth and global distribution, we are positioned to offer holistic, science-backed solutions that address the root causes of animal health challenges.”
Manish Gaur, Board Member of Zenex and MD & Head of Pharma and Healthcare at Multiples, added, “We are excited about the combination with VievePharm, as it strengthens Zenex’s ability to provide science-backed, herbal alternatives to markets that are increasingly favouring natural products. Strategic acquisitions that provide important capability additions, like VievePharm’s bolus technology and European footprint, will continue to be a vital part of the value-creation journey at Zenex as we scale our leadership globally.”
Arie Boorsma, Founder of VievePharm, said, “Joining forces with Zenex allows us to scale our 'Best of Nature' philosophy to a global stage. Our commitment to sustainable livestock farming and innovation in animal nutrition aligns perfectly with Zenex’s vision. This partnership will provide the resources and reach necessary to deepen our operations in The Netherlands and take our solutions to farmers across Europe and RoW markets.”
